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Introduction
Clinical practice guidelines are “systematically developed
statements to assist practitioner and patient decisions
about appropriate health care for specific clinical circum-
stances” [1]. During the past 10 years, there has been a
proliferation of clinical practice guidelines published in
peer-reviewed literature. However, guidelines developed
by different groups addressing the same clinical scenario
have resulted in conflicting treatment recommendations
[2]. Furthermore, recently completed structured evalua-
tions of clinical practice guidelines led by Grilli [2] and
Shaneyfelt [3] have raised concerns about the method-
ological quality of the guidelines’ development.
Within the field of rheumatology, a number of clinical prac-
tice guidelines have recently been developed. In the year
2000, both the American College of Rheumatology (ACR)
[4,5] and the European League Against Rheumatism
(EULAR) [6] released guidelines for the medical manage-
ment of lower-limb osteoarthritis (OA).
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Abstract
Clinical practice guidelines are important tools to assist clinical decision-making. Recently, several
guidelines addressing the management of osteoarthritis (OA) have been published. Clinicians treating
patients with OA must ensure that these guidelines are developed with consistency and
methodological rigour. We undertook a qualitative summary and critical appraisal of six medical
treatment guidelines for the management of lower-limb OA published in the medical literature within
the past 5 years. A review of these six guidelines revealed that each possesses strengths and
weakness. While most described the scope and intended patient populations, the guidelines varied
considerably in the rigour of their development, coverage of implementation issues, and disclosure of
conflicts of interest.
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OA is the most common form of arthritis [7]. It is a leading
cause of chronic health problems and long-term disability
and creates a significant economic burden for health ser-
vices [8,9]. To date, however, the methodological quality
of the various guidelines for the treatment of OA has not
been formally evaluated and compared.
We performed a systematic literature search and evaluation
of treatment guidelines for lower-limb OA. Our aim was to
qualitatively document the recommendations provided
within the guidelines, and quantitatively assess the methods
used to develop them. The guidelines are intended for
clinicians, who do not have the time to chase down addi-
tional information about their methodological development.
We believe that guidelines should be reported in sufficient
detail to allow clinicians to make judgements about the
validity of their recommendations [10]. Therefore, we limited
our evaluation of the guidelines to published materials or
information easily accessible on the internet only.
Methods
The panel of four reviewers was comprised of an allied
health professional and arthritis researcher (JP), a primary-
care physician (GJ), a community rheumatologist (EG),
and an academic rheumatologist and clinical epidemiolo-
gist (CB).
Our first step was to identify all relevant practice guide-
lines. To ensure the guidelines and recommendations were
relevant and up to date, we evaluated only those published
within the past 5 years. We searched OVID MEDLINE and OVID
EMBASE using the following search strategy:
1. Osteoarthritis or osteoarthrosis or degenerative arthri-
tis (Medical Subject Headings [MeSH] or keyword in
title or abstract)
2. Practice guideline[s] or consensus development con-
ference[s] (MeSH or publication type or keyword in
title or abstract)
3. Standard[s] of Care or Practice Standard[s] or Prac-
tice Policy or Practice Parameter[s] or Practice Proto-
col[s] or Clinical Algorithm[s] or Practice Algorithm[s]
or Guideline[s] or Recommendation[s]
4. 2 or 3
5. 1 and 4
The reference lists of all identified guideline documents
were reviewed for other potential guidelines to be
included in the evaluation.
Potential guidelines were reviewed for inclusion into the
evaluation using specific criteria, based on Field and
Lohr’s [1] definition of practice guidelines. The guidelines
chosen for review must have:
• been specific to the condition of OA. If it included
other chronic pain or rheumatic conditions, then the
discussion of OA must have been major focus.
• addressed the treatment of OA. Although some guide-
lines included clinical algorithms, a major focus of the
guideline must have been treatment. It must have
addressed either pharmacological or nonpharmacolog-
ical therapy or both. Diagnostic and surgical guidelines
were excluded. The guideline must have addressed a
group or class of treatments (e.g. nonsteroidal anti-
inflammatory drugs [NSAIDs] or opioid analgesics), not
a single treatment (e.g. morphine).
• included a summary of the literature or evidence relat-
ing to the treatments discussed. The literature
summary did not have to be a systematic one.
• been published in English.
• represented the opinions of at least five health profes-
sionals.
The MEDLINE and EMBASE searches identified 134 and 147
citations, respectively. Of these, 128 from MEDLINE and
142 from EMBASE were immediately excluded from consid-
eration, because they were either non-English, editorials,
letters to the editor, news stories or announcements, clini-
cal studies, or clinical reviews. There remained 11 cita-
tions (6 from MEDLINE and 5 from EMBASE), of which we
retrieved full text copies for review using the inclusion cri-
teria described above.
Of the 11 potential documents [4–6,11–18], six met our
inclusion criteria and were evaluated by the panel
(Table 1). Five potential guidelines were excluded: four
because they were clinical reviews and one because it
was a duplicate of the EULAR guidelines. Each reviewer
was provided with a package containing all the guidelines,
background reading on the development and usage of
guidelines, and copies of an instrument for the evaluation
of guidelines, Appraisal of Guidelines for Research & Eval-
uation (the AGREE instrument).
This AGREE instrument was developed for use in assess-
ing the quality of clinical guidelines [19]. It is the product
of work coordinated by the AGREE Collaboration, an
international panel of guideline experts charged with
improving and standardizing all aspects of guideline devel-
opment, implementation, and monitoring [20]. The instru-
ment contains six themes, comprising 23 items, as well as
an overall guideline global assessment of quality. The six
themes are: scope and purpose, stakeholder involvement,
rigour of development, clarity and presentation, applicabil-
ity, and editorial independence. The guidelines’ fulfilment
of each item was rated on a 4-point response scale, from
4 = strongly agree to 1 = strongly disagree.
Each of the four reviewers independently evaluated the
guidelines using AGREE. The panel then met and attained
consensus on the majority of item ratings through informal
discussion of each set of guidelines. The reviewers also dis-
cussed general strengths and weaknesses of the guidelines.Arthritis Research    Vol 4 No 1 Pencharz et al.
Results
Two of the six guidelines were restricted to the evalua-
tion of NSAIDs: the Second Canadian Consensus Con-
ference described evidence-based prescribing of
NSAIDs for patients with OA or rheumatoid arthritis [11],
while the North of England evidence-based guideline
addressed the use of NSAIDs compared with basic anal-
gesia in degenerative arthritis [12,13]. We also identified
two comprehensive clinical algorithms: one entitled
‘Algorithms for the Diagnosis and Management of Mus-
culoskeletal Complaints’ (ADMMC) [14–16] and the
other, developed by the Institute for Clinical Systems
Improvement (ICSI), focusing on the diagnosis and treat-
ment of adult degenerative joint disease of the knee
[17,18]. The other two guidelines were developed by
professional bodies in rheumatology, the ACR [4,5] and
the EULAR [6], and are comprehensive treatment guide-
lines addressing both pharmacological and nonpharma-
cological management.
The two guidelines restricted to the evaluation of non-
steroidal anti-inflammatory medication, the North of
England Guidelines and the Canadian Consensus Guide-
lines, are described in the next two sections. The remain-
ing four are then presented in a table.
North of England guideline
The North of England evidence-based guideline [12,13]
compared the use of NSAIDs with basic analgesia (i.e.
paracetamol) in treating the pain of degenerative arthritis.
The guideline addressed efficacy, gastrointestinal safety,
and economic considerations. Its primary treatment rec-
ommendations were:
1. Paracetamol (acetaminophen) is the initial treatment of
choice: up to doses of 4 g daily.
2. If paracetamol fails to provide symptomatic relief, then
ibuprofen, at daily doses of 1.2 g, is the most appropri-
ate alternative.
Table 1
Attributes of osteoarthritis treatment guidelines published within the past 5 years
Year 
literature 
Guideline Year  search 
[Reference no.] published completed Guideline development attributes End users
Canadian Consensus  2000 Not stated Rheumatologists; general and family practitioners Primary-care physicians, 
Conference [11] Grading of evidence rheumatologists
Formal consensus methods for recommendations
External review
North of England [12,13] 1998 Not stated Multidisciplinary committee Primary-care physicians
(Does state that Meta-analyses of evidence
recommendations  Grading of evidence
cease to apply  Informal consensus for recommendations
December 1999) Recommendation strength grading
External review
Algorithms for the  1997 Not stated Multidisciplinary committee Primary-care physicians
Diagnosis and Management Grading of evidence
of Musculoskeletal  Formal and informal consensus methods for 
Complaints (ADMMC)  recommendations
[14–16,33] Formal approval process by stakeholders
ICSI[17,18] 1999 (2000) Not stated Multidisciplinary committee Physicians, nurses, allied
Grading of evidence health professionals, 
Assume informal consensus for recommendations health policy makers
External review health care researchers
EULAR [6] 2000 December 1998 Rheumatologists, orthopaedic surgeons, and  Not stated
guideline methodologists
Meta-analyses of evidence
Grading of evidence
Delphi consensus method
Recommendation strength grading
Internal review
ACR[4,5] 2000 Not stated Rheumatologists Not stated
Informal grading of evidence
Informal consensus for recommendations
External review
ACR = American College of Rheumatology; EULAR = European League Against Rheumatism; ICSI = Institute for Clinical Systems Improvement.3. If further pain relief is needed, clinicians should con-
sider increasing the dosage of ibuprofen to daily doses
of 2.4 g, or using ibuprofen and paracetamol in combi-
nation, or using an alternative NSAID (i.e. diclofenac or
naproxen), or initiating co-codamol (codeine).
The guideline discussed potential gastrointestinal side
effects of NSAIDs. It encouraged clinicians to monitor
patients closely for gastrointestinal toxicity and to review the
need for chronic NSAID therapy regularly. Although the
authors of the guideline acknowledged evidence supporting
the use of misoprostol and proton pump inhibitors (PPIs) in
preventing gastrointestinal injury, these therapies were not
recommended routinely for all patients, with the possible
exception of a selected group of high-risk patients (e.g. with
a previous gastrointestinal bleed). Additionally, H2 antago-
nists and PPIs may have a small impact on dyspepsia, but
the benefits do not appear to exceed those from antacids.
From a cost–benefit perspective, the North of England
guideline concluded that paracetamol and ibuprofen
should be first- and second-line therapies, respectively,
and that modified-release preparations are no more effec-
tive than standard treatment, while prophylactic use of
misoprostol or PPIs is not cost effective.
Canadian Consensus Conference
The Canadian Consensus Conference [11] for the evi-
dence-based use of NSAIDs in the treatment of OA and
rheumatoid arthritis is a revised version of a NSAID guide-
line document first released in 1995. The guideline
addressed issues of clinical efficacy, patient tolerability,
gastrointestinal toxicity, renal toxicity, hypertension, and
interactions with anticoagulants.
The primary recommendations were that NSAIDs should
be the pharmacological agent of choice for patients with
moderate to severe OA, while acetaminophen (paraceta-
mol) can be considered as primary therapy in mild OA and
as an adjunct therapy in moderate or severe OA. The
authors of the guideline emphasized that decisions about
the choice of pharmacological management should be
made in concert with patients after discussing a drug’s
efficacy, safety, tolerability, and cost.
The Canadian Consensus Conference recommended
cyclooxygenase-2 (COX-2) inhibitors as first-line therapy for
patients with risk factors for a PUB (perforation, ulcer,
bleed). The guideline stated that PPIs or misoprostol should
be coadministered with any NSAID in patients with a history
of an upper gastrointestinal bleed in the preceding 4 to
6 weeks. In patients with a history of an ulcer, testing for
and eradicating Helicobacter pylori was recommended.
The Canadian Consensus Conference guideline grouped
all NSAIDs (i.e. both nonspecific and COX-2-specific) as
having similar effects on renal function and emphasized the
need to monitor glomerular filtration rate (GFR). The guide-
line recommended that patients with hypertension have
their blood pressure checked one week after being started
on an NSAID and that a patient’s antihypertensive medica-
tion dose or type may need to be modified appropriately.
Finally, this guideline indicated that COX-2-specific
inhibitors should be selected over nonspecific NSAIDs in
patients on anticoagulants (e.g. warfarin). Furthermore, a
patient’s international normalized ratio (INR) should be
monitored frequently during the first week of NSAID use
and warfarin doses should be modified appropriately.
ADMMC, ICSI, EULAR and ACR guidelines
Four of the guidelines we reviewed contained comprehen-
sive recommendations for both pharmacological and non-
pharmacological management of OA [4–6,14–18]. Their
recommendations are summarized in Table 2. These
guidelines indicated that nonpharmacological therapy
such as patient education, social support, physical and
occupational therapy, and exercise should be initiated as
soon as possible and should represent the mainstay of
therapy. Other nonpharmacological modalities recom-
mended in some of the guidelines were weight loss,
energy conservation, joint protection, heat, ice, acupunc-
ture, massage, and electrical stimulation.
Similar to the North of England and Canadian Consensus
guidelines, the four comprehensive guidelines recommend
the use of acetaminophen (paracetamol) as the initial
pharmacological therapy in mild OA. While the use of
NSAIDs was suggested in all the guidelines if aceta-
minophen failed to control joint pain, the ACR guideline
supported using NSAIDs as initial pharmacological
therapy in patients with moderate to severe OA. COX-2-
specific NSAIDs were recommended in the ACR guide-
line, and although they were not discussed in the
published version [17], the ICSI guideline does recom-
mend the use of COX-2-specific NSAIDs in its web
update [18]. Because its literature search extended only
up to December 1998, the EULAR guideline did not
address the use of the COX-2 inhibitors. Conversely, the
authors of the North of England guideline, which also
excluded a discussion of COX-2-specific NSAIDs,
acknowledged that information about new therapies would
probably be available before their guideline’s stated expiry
date of December 1999.
Other pharmacological agents recommended as individual
or adjunct therapies were opioid analgesics, cortico-
steroid or hyaluronic acid injections, and capsaicin cream.
The ACR guideline provides the most comprehensive
review of medication toxicity, including recommending
using either misoprostol or PPIs as gastroprotective
agents, whereas the ADMMC guideline only recom-
Available online http://arthritis-research.com/content/4/1/036
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Table 2
Recommended therapies or modalities considered in four comprehensive treatment guidelines for lower-limb osteoarthritis
published within the past 5 yearsa
Guideline [reference]
ADMMC OA [14–16]  EULAR [6] (Strength of 
Therapy/modality (Grade of evidenceb) ICSI [17,18] recommendationc) ACR [4,5]
Acetaminophen Recommended (A) Recommended Recommended (A) Recommended 
(mild to moderate OA)
NSAIDs Recommended (A) Recommended Recommended (A) Recommended 
(moderate to severe OA)
Cox-2-specific NSAIDs Not discussed Recommended  Not discussed Recommended 
(2nd-line therapy) (2nd-line therapy in patient 
with high gastrointestinal risk)
Corticosteroid joint injection Recommended (A) Recommended Recommended (A) Recommended
Hyaluronic acid joint injection Recommended (A) Recommended Recommended (B) Recommended
Capsaicin cream Recommended (A) Recommended Recommended (A) Recommended
Other topical cream  Not discussed Recommended Recommended (A) Recommended
(e.g. NSAID cream)
Opioid analgesics Recommended (B) Recommended Recommended (B) Recommended
Aerobic exercise Recommended (A) Recommended Recommended (A) Recommended
Strengthening and  Recommended (B) Recommended Recommended (A) Recommended
range-of-motion exercise
Education Recommended (no grade) Recommended Recommended (A) Recommended
Arthritis self-management  Recommended (A) Recommended Recommended (A) Recommended
education
Physical therapy Recommended (no grade) Recommended Recommended Recommended
Occupational therapy Recommended (C) Recommended Recommended Recommended
Telephone contact Recommended (A) Recommended Recommended (B) Recommended
Weight loss Recommended (B) Recommended Recommended (B) Recommended
Walking assistive devices  Recommended (C) Recommended Recommended (B) Recommended
(e.g. shoe inserts, cane)
Assistive devices for  Recommended (C) Recommended Not discussed Recommended
activities of daily living
Glucosamine (with or  Not discussed Recommended Recommended (A) Not recommended
without chondroitin)
Knee brace or taping Not discussed Not discussed Recommended (B) Recommended
Hot pack or ice pack Recommended (no grade) Recommended Not discussed Recommended
Joint protection techniques Recommended (no grade) Recommended Recommended (A) Recommended
Planning activities Recommended (no grade) Recommended Recommended (A) Recommended
Acupuncture Not discussed Recommended Not discussed Not recommended
Electrical stimulation (e.g. TENS) Not discussed Recommended Not discussed Not discussed
Massage Not discussed Recommended Not discussed Not discussed
aThis table covers only the four comprehensive treatment guidelines. For summary of recommendations of NSAID-specific guidelines, see Results
section. bGrade of evidence: A = at least one high-quality randomized controlled trial with adequate power; B = evidence from underpowered
randomized controlled; prospective controlled or historical controlled studies; C = consensus/expert opinion/uncontrolled trials; no grade = the
therapy/modality was discussed in the text of the guideline, no level of evidence was provided to support the therapy/modality. cStrength of
recommendation: A = directly based on category-1 evidence (meta-analysis of one or more randomized, controlled trials; B = directly based on
category-2 evidence (at least one controlled study without randomization or at least one quasi-experimental study) or extrapolated
recommendations from category-1 evidence; C = directly based on category-3 evidence (descriptive studies, such as comparative studies,
correlation studies, or case–control studies) or extrapolated recommendations from category-1 or -2 evidence; D = directly based on category-4
evidence (expert committee reports or opinions and/or clinical experience of respected authorities) or extrapolated recommendations from
category-2 or -3 evidence. ACR = American College of Rheumatology; ADMMC = Algorithms for the Diagnosis and Management of
Musculoskeletal Complaints; COX-2 = cyclooxygenase-2; EULAR = European League Against Rheumatism; ICSI = Institute for Clinical Systems
Improvement; NSAID = nonsteroidal anti-inflammatory drug; OA = osteoarthritis; TENS = transcutaneous electrical nerve stimulation.Available online http://arthritis-research.com/content/4/1/036
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mended the use of misoprostol as a gastroprotective
agent. The EULAR and ICSI guidelines failed to describe
an approach to gastroprotection.
Quantitative evaluation of the guidelines using the
AGREE instrument
The quantitative evaluation of the guidelines using the
AGREE instrument is summarized in Table 3. We scored
each set of guidelines on each item of the AGREE instru-
ment, using a 4-point scale ranging from 4 = strongly
agree to 1 = strongly disagree. For reasons of clarity, we
have dichotomized this scale. Guidelines were deemed to
have fulfilled an item (indicated by + in Table 3) if the
reviewers rated the guidelines as 3 or 4 on that item. Con-
versely, if the reviewers rated a guideline as 1 or 2 on any
of the items then the item was deemed to have not been
fulfilled (indicated by – in Table 3). In cases where one of
the reviewers disagreed with the other three reviewers (i.e.
rated the guideline as 3 or 4 when the other reviewers
rated it as 1 or 2, or vice versa), the judgement of the
majority of reviewers is reported in Table 3 and the opinion
of the dissenting reviewer is indicated by the “b”.
In general, the AGREE instrument was easy to apply to
each of the guidelines and there were few disagreements
between the reviewers. The scope and purpose for each
guideline was usually clearly stated, but the stakeholder
involvement in the development process was not always
well described and varied considerably across guidelines.
Although many of the guidelines were based on consulta-
tions with a range of health professionals caring for
patients with arthritis, some tended to rely more on input
from a narrow set of specialists [4–6] and only a few
reflected formal consideration of patients’ preferences
[4,5,11]. The European guidelines [6,12,13] tended to be
based on a more systematic approach to searching, select-
ing, and summarizing the evidence, but in all the guidelines,
recommendations were explicitly linked to supporting evi-
dence. In some, the strength of the supporting evidence
was scored according to a predefined scale [6,12–18].
Only two contained results pooled across trials by the use
of formal, quantitative meta-analysis tools and provided
summary effect sizes for specific therapies [6,12,13]. In all
six guidelines, recommendations were clearly highlighted
and were supported at least by reference citations.
In contrast, most of the guidelines failed to adequately
consider the important issues of dissemination, implemen-
tation, and applicability. The only exception was the ICSI
guideline, which was specifically designed for implementa-
tion in a US Health Maintenance Organization [17,18]. In
this guideline, efforts were put into the design of clinical
decision tools and review criteria to monitor the success
of its implementation. Finally, disclosure of financial
support for the guideline process and independence from
the funding body was poorly reported.
Discussion
Clinical practice guidelines will play an increasing role in
clinical and health policy decision-making in the upcoming
years. Consequently, the methodology used to develop
guideline recommendations must be transparent and open
to critical analysis, as in other areas of peer-reviewed
research. Recent critiques of the guidelines have cast
doubt on the recommendations brought forth by both the
EULAR [21] and the ACR [22]. The scientific and clinical
basis for those charges are outside the scope of this
review.
We have made a qualitative summary (see Table 2) and a
quantitative evaluation (see Table 3) of the content of
treatment guidelines for lower-limb OA. The guidelines
contained similar recommendations for both nonpharma-
cological and pharmacological therapies (see Table 2).
This was particularly true in areas where there is strong
evidence for the usefulness of certain nonpharmacological
therapies (e.g. education, muscle strengthening, aerobic
exercise, telephone contact) and pharmacological (e.g.
acetaminophen, NSAIDs, opioids, hyaluronic acid injec-
tions). Conversely, in the case of therapies for which the
evidence of usefulness is sparse or still accumulating (e.g.
acupuncture, massage, glucosamine), either no recom-
mendations were made or there was disagreement
between guidelines.
In other fields, researchers have also found that guideline
recommendations often diverged in areas of weaker evi-
dence [23,24]. They believed that such disagreement
could be explained by failure of the guideline developers
to follow sound methodological principles in the forma-
tion of the guideline document [3]. We used the AGREE
instrument, which incorporates six distinct themes of
guideline development and implementation, to evaluate
the methodological development of treatment guidelines
for OA.
Scope and purpose
All the guidelines clearly stated their scope and purpose,
which should help a prospective clinician identify the
appropriate patient population to whom the guidelines
should apply.
Stakeholder involvement
The authors of some of the guidelines elicited expert
input only from a narrow group of specialists [4–6], which
could lead to implementation difficulties [25]. This is par-
ticularly true when targeted health professionals, such as
primary-care physicians or allied health professionals,
were not included in the development process [2]. Fur-
thermore, only the Canadian Consensus and ACR guide-
lines explicitly incorporated patient preferences into their
recommendations.Arthritis Research    Vol 4 No 1 Pencharz et al.
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.Rigour of development
Within the guidelines that we evaluated, there existed
shortcomings in the descriptions of the literature-search
processes and how the evidence was subsequently
selected for inclusion in the guideline. Three of the guide-
lines failed to appropriately describe how the literature
was identified and selected, thereby raising the question
of whether the literature review was comprehensive and
unbiased in its coverage of the area of interest [26].
However, most of the OA guidelines clearly highlighted
the link between evidence and recommendation by provid-
ing a table summarizing the evidence for each recommen-
dation and, in some instances, the strength ratings of that
evidence.
Although most guidelines called for external review from
experts, stakeholders, and end users, a more explicit
description of the external reviewers and the reason for
their selection could have been provided.
To ensure that recommendations are relevant and timely, a
method to monitor changes in the field and identify the
need for modification of guideline recommendations
should be implemented [27]. All but one guideline made
reference to the need for revisions in the future, but they
did not explicitly describe how this process would occur.
This is particularly relevant given that two of the guidelines
[6,14–16] failed to address the use of COX-2 inhibitors
and two [6,17,18] failed to discuss gastroprotection
during chronic long-term NSAID use. The failure of the
guidelines to address these issues is due predominantly
to the time frame of their literature searches.
Clarity and presentation
The key recommendations from most of the guidelines are
clearly identifiable. Some of the guidelines embedded their
recommendation with the text of a paragraph [4,5,11]
located under a section heading, while others separately
highlighted [6,12,13] their recommendations using italics
at the beginning of a paragraph containing the discussion
of that recommendation. We found the latter method a
more effective technique for delivering guideline recom-
mendations [28].
Applicability
Here we refer to the pilot testing and implementation barri-
ers that must be overcome before the recommendations
of a guideline are incorporated into everyday practice. In
this respect, there is a clear weakness in the guidelines
we reviewed, as almost none addressed implementation
strategies. Implementation difficulties, however are often
related more to political and organizational barriers than to
scientific disagreements [29]. In addition, guidelines need
to be adapted to local practice environments, because
some treatment modalities may not be available locally
(e.g. pool facilities, muscle strengthening equipment,
COX-2-specific NSAIDs) [30]. All but the ICSI guidelines
failed to address these difficulties adequately.
“Guidelines do not implement themselves” [1]. Continual
monitoring of guideline implementation is essential. Devel-
opers can provide aids for clinicians and patients, such as
a quick reference guide, patients’ leaflets, or reminders in
the patient chart, to help promote their use in clinical prac-
tice [31]. Furthermore, guideline developers should iden-
tify key review criteria or indicators that clinics or
physicians should evaluate to determine the success of
guideline implementation. The only guideline to fulfill this
item was that of the ICSI.
Editorial independence
Guideline developers should fully disclose their funding
sources, their editorial independence from their funding
sources, and any other potential conflicts of interest. Full
disclosure is necessary to ensure that any biases (or, more
importantly, the perception of any biases) are acknowl-
edged [22]. Although only two of the guidelines did not
state their funding source, none of the guidelines com-
pleted all three of the disclosure tasks.
General comments
Because we have reviewed guidelines published in the
peer-reviewed literature, we have captured a select group
of OA treatment guidelines. Many guidelines developed by
governmental or reimbursement agencies are never
published in a peer-reviewed journal. To provide a review of
these guidelines was beyond the scope of this appraisal.
Paradoxically, however, guidelines developed locally are
often the most effective at being accepted by end users
and result in changes in professional practice [32].
Conclusions
We were interested in evaluating the methodological
quality of treatment guidelines for lower-limb OA published
in the peer-reviewed literature. Treatment recommenda-
tions agreed substantially between guidelines. However,
the methodological quality of the guidelines varied and
could generally be improved. Some of the guidelines failed
to adequately incorporate the views of all stakeholders (e.g.
patients, primary-care physicians, allied health profession-
als). We were particularly surprised by the failure of the
authors of some of the guidelines to illustrate that their liter-
ature search, synthesis, and recommendation development
processes were sufficiently rigorous. Furthermore, none of
the guidelines addressed the ‘doability’ (i.e. implementation
difficulties) of their recommendations. Future guideline
developers in the field of rheumatology would benefit from
transparent documentation of the process of their guideline
development and its susceptibility to sources of bias.
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